1 · Payrolls at 14:30 CEST
Dow Jones consensus is +84,000 jobs and 4.1% unemployment. No September result existed at cutoff. A wage/revision surprise matters as much as the headline. CNBC · BLS
Friday · Asia close / Europe pre-open / U.S. premarket
Aman's Global Market Intelligence — 2026-10-02
NEUTRAL / CAUTIOUS — POSITIVE FUTURES, OIL AND PAYROLL RISK
U.S. futures are modestly positive and Thursday breadth improved, but Asian risk appetite weakened, the 10-year briefly reached a 2002-era high, and Middle East escalation pushed oil sharply higher. The jobs report is the day's dominant binary catalyst.
Executive dashboard
S&P 5007,666.45+0.19% Thu · ES +0.26%
Nasdaq Composite26,871.60+0.04% · NQ +0.33–0.42%
Dow50,926.56+0.04% · YM +0.24–0.33%
Russell 20002,806.63+0.35% · RTY +0.37%
VIX16.39+0.31% Thu
U.S. 2Y / 10Y4.78% / 5.24%Official Oct. 1 closes
Dollar index101.87−0.23% early Fri
WTI crude$92.18After $92.87 Thu settlement
Gold futures$4,219.90+0.42% early Fri
Nikkei 22568,219−1.07% Fri
Hang Seng23,965−2.63% Fri
Europe Thu closesSTOXX50 6,175−1.49% · FTSE −1.68% · DAX −1.03%
Prices: Yahoo Finance chart API snapshots at 08:21–08:30 CEST, cross-checked against CNBC's live market report. CNBC showed ES +0.26%, Nasdaq-100 futures +0.42%, Dow futures +0.24%, Nikkei −0.95%, KOSPI −1.0% and HSI −2.48% at its earlier timestamp; small differences are timestamp/provider effects. Official curve: U.S. Treasury.
2 · Oil revives inflation risk
Brent settled above $102 and WTI at $92.87 after reporting that the U.S. was sending a third carrier strike group to the Middle East. Energy strength is a tax on duration and non-energy margins. CNBC
3 · AI leadership broadens selectively
MU +3.03%, NVDA +1.09%, COHR +10.90% and CRDO +7.90%, while AVGO fell 2.15%. Optical/interconnect strength is real, but the largest moves lack a same-day primary release and should not be chased.
Global session map
| Region | Verified state | Read-through | Caveat |
|---|---|---|---|
| United States | All four major cash indices modestly higher Thursday; futures +0.24% to +0.42% early Friday. | Constructive positioning into payrolls, not conviction after payrolls. | Cash market opens 15:30 CEST, one hour after the report. |
| Japan / Korea | Nikkei about −1.07%; CNBC reported KOSPI −1.0%. | Profit-taking after Thursday's semiconductor surge. | High index concentration amplifies chip moves. |
| Hong Kong / China | HSI −2.63% after holiday; Shanghai last 3,842 from Sept. 30. | Clear regional risk-off signal. | Mainland cash reference is stale because of holiday closure. |
| Europe | Cash market not open at cutoff; Thursday STOXX 50 −1.49%, FTSE −1.68%, DAX −1.03%. | Prior-session weakness and energy/rate pressure argue for caution. | No Friday cash return is claimed. |
Market drivers
Macro, central banks and rates
- Jobs: consensus +84k and 4.1% unemployment; a strong report combined with oil could lift real/nominal yields, while a weak report with negative revisions could challenge growth. CNBC
- Rates: CNBC said the 10-year touched 5.344%, its highest since 2002, before retreating. Treasury's official Oct. 1 close was 5.24%; 2Y fell 10 bp to 4.78%, steepening 2s10s to +46 bp. Treasury
- Fed: futures implied a 72% probability of no October change in CNBC's overnight snapshot. Treat that as timestamp-dependent, not a forecast. CNBC
- Calendar: Sept. 15–16 FOMC minutes arrive Oct. 7; next meeting Oct. 27–28. Federal Reserve
Geopolitics, earnings, regulation and rotation
- Energy shock: Thursday's Brent +4% to $102.31 and WTI +2.7% to $92.87 raise near-term inflation and freight/input-cost risks. CNBC
- Breadth: Russell +0.35% outpaced mega-cap indices Thursday, but Asia sold off Friday and Europe had fallen Thursday. This is mixed global breadth.
- SEC: the regulator proposed a new framework addressing custody of crypto assets by advisers and funds on Oct. 1. It is a proposal, not final law. SEC
- Rotation: optical connectivity outperformed accelerators, while AVGO declined 2.15%; do not treat “AI” as a single factor.
Theme dashboards
Demand evidence; valuation dispersion
- MU closed $1,097.39, +3.03%, above its 20-day average near $1,019 after Wednesday's record results; NVDA closed $230.86, +1.09%, above its 20-day average near $223.51.
- NVIDIA's Oct. 1 newsroom says GPT-6 Astra Ultrafast runs on Blackwell GPUs—fresh platform evidence, but not disclosed revenue. NVIDIA
- COHR +10.90% on 1.79× 20-day volume and CRDO +7.90%; Coherent's latest listed primary release was Sept. 21 PhotonLink, not an Oct. 1 catalyst. Coherent
- VRT +1.99% but remains below its 20-day average; power/cooling has not regained prior leadership. Main risks: 5%+ yields, AI ROI, capex digestion, export rules and crowded multiples.
Milestones improve; economics still thin
- IONQ +0.30%; QBTS −0.06%; RGTI −0.76%; QUBT −0.71%, all on below-20-day-average volume. No basket breakout.
- D-Wave launched a gate-model simulator beta Oct. 1—technical/product progress, not evidence of material recurring profit. D-Wave
- IonQ's latest listed release was Sept. 24, after several September technical/partnership announcements; its Q2 adjusted EBITDA loss was $120.3m. IonQ IR
- Risks: pre-profit cash burn, stock compensation/dilution, milestone execution, modality competition and squeezes. No borrow availability or fee is assumed.
Positive science, weak tape
- NVO fell 1.35% to $37.40, a new 20-day intraday low, despite company-reported EASD data that 9 of 10 adults with obesity/excess liver fat normalized liver fat on Wegovy. The release headline alone does not establish trial design, multiplicity or commercial increment. Novo
- LLY fell 0.62% to $1,149.85; retatrutide Phase 3 efficacy remains promising, but GI events, dysesthesia and regulatory/CMC review remain material.
- VKTX fell 6.41% to $30.51; no approved product and binary Phase 3/financing risk argue against bottom-fishing.
- EMA's Oct. 1 update contained no new peptide-obesity approval listed in the accessible feed. EMA
Ranked ideas · initial two-week paper tracking
Today is event-first: two conditional longs, one avoid basket and five watch-only setups. Entries require live post-payroll confirmation. Confidence scores evidence quality, not guaranteed probability.
Bullish / constructive
#1 Conditional bullish
NASDAQ · large-cap memory semiconductor · high/cyclical riskMU — Micron Technology
Classification: post-earnings continuation, uncertain direction. Applicable horizons: day trade and 1–4 week swing; 3–12+ months only with memory-cycle monitoring.
Thesis / catalystRecord FY26 results and above-consensus fiscal Q1 guidance remain the freshest hard AI-demand evidence; Thursday's +3.03% close confirmed more than the muted initial after-hours response. Micron IR
Evidence / counterargumentClose $1,097.39, above ~$1,019 20-day average, but just under the $1,108.72 20-day high. Counter: extreme prior appreciation, cyclicality and exceptional current margins leave little error tolerance.
Entry / confirmationDay/swing only after payrolls: hold above $1,098.90 Thursday high, then clear $1,108.72 on solid SOX breadth. Do not chase an opening gap.
Invalidation / downsideDay invalidation below $1,022.90 Thursday low; swing invalidation on close below ~$1,019. Gap risk can exceed stops.
Fundamental / technicalContracted HBM demand and cash generation support thesis; high valuation/cycle expectations and a 5%+ 10Y constrain multiple expansion.
Key risksDRAM/HBM pricing, oversupply, Samsung/SK Hynix, customer concentration, China/export rules, capex and payroll-driven rates.
#2 Conditional bullish
NASDAQ · mega-cap accelerator/platform · high riskNVDA — NVIDIA
Classification: quality AI trend-follow; uncertain pre-payroll. Applicable horizons: day, 1–4 weeks and staged 3–12+ months.
Thesis / catalystBlackwell deployment for OpenAI's GPT-6 Astra and Micron's HBM demand support the compute stack; NVDA gained 1.09% Thursday. NVIDIA newsroom
Evidence / counterargument$230.86 is above the $223.51 20-day average. Counter: still below the $234.76 20-day high; custom silicon, exports and rates pressure the multiple.
Entry / confirmationRequire post-jobs hold above $232.29 Thursday high; stronger swing confirmation above $234.76 with semiconductor breadth. Prefer a higher low to a gap chase.
Invalidation / downsideDay below $228.16; swing close below ~$223.51. Long-term: guide deceleration, estimate cuts or structural gross-margin erosion.
Fundamental / technicalHigh liquidity and positive relative trend; Thursday volume was only 0.87× its 20-day average, so breakout confirmation is incomplete.
Key risksExport restrictions, TSMC/packaging, hyperscaler concentration, AI ROI, custom accelerators, power constraints and duration valuation.
Bearish / short / avoid
#1 Avoid chase · not a short
NYSE/Nasdaq · small/mid-cap, mostly pre-profit · extreme riskIONQ / QBTS / RGTI / QUBT — pure-play quantum basket
Classification: tactical avoid; direction highly uncertain. Applicable horizons: day and 1–4 weeks; 3–12+ months only as venture-risk exposure. No borrow claim.
Thesis / catalystD-Wave's simulator beta is legitimate progress, but Thursday prices/volumes did not confirm sector-wide repricing and 5%+ long yields penalize distant cash flows.
Evidence / counterargumentIONQ alone is above its 20-day average; QBTS/RGTI/QUBT are near or below theirs, all four on 0.63–0.75× average volume. Counter: contracts, benchmark proof or funding can gap shares sharply.
Entry / confirmationNo naked short. Avoid stance strengthens below IONQ $43.55, QBTS $16.40, RGTI $15.51 and QUBT $8.32. Reconsider only on verified economics plus volume-backed basket breakouts.
Invalidation / downsideInvalidated tactically above IONQ $47.91, QBTS $18.93, RGTI $17.66 and QUBT $9.76 on volume. Short losses can be unlimited.
Fundamental lensTrack organic revenue, customer acceptance, bookings conversion, cash burn and fully diluted shares—not qubit counts or partnerships alone.
Key risksDilution, roadmap slippage, thin liquidity, modality competition, government milestone conditions and violent squeezes.
Watchlist — no active entry
COHR — Coherent
NYSE · large-cap photonics · high risk. Classification/horizon: watch pullback; day and 1–4 weeks, staged 3–12+ months. Direction uncertain after +10.90%.
Thesis/catalyst: optical connectivity benefits from AI scale-out; PhotonLink launched Sept. 21. Evidence/counter: $319.19 close, 1.79× volume, above $294.59 20-day average; no Oct. 1 primary catalyst was listed, and the stock remains below $332.86 20-day high. Entry: hold $286.42–$290 after a pullback or close above $323.23 then $332.86. Invalidation/downside: close below $286.42, then $255.25. Risks: unexplained momentum, customer concentration, optical cycle, execution, leverage/multiple and gap reversal. Primary releases
CRDO — Credo Technology
NASDAQ · mid/large-cap connectivity semiconductor · very high risk. Classification/horizon: watch, no chase; day and 1–4 weeks. Thesis/catalyst: AI active-electrical/optical connectivity demand. Evidence/counter: +7.90% to $210.17, above $178.52 20-day average but near $214.87 20-day high; volume was only 0.94× the accessible 20-day average, weakening breakout quality. Entry: close above $214.87 with volume or orderly higher low above $195. Invalidation/downside: close below $195, then $178.52. Risks: customer concentration, competition, inventory, rich expectations and sharp beta. Credo IR
VRT — Vertiv
NYSE · large-cap infrastructure · high risk. Classification/horizon: watch reclaim; 1–4 weeks and 3–12+ months. Thesis/catalyst: rising rack density supports power/cooling demand. Evidence/counter: +1.99% to $246.12, but still below $252.10 20-day average on 0.65× volume. Entry: close above $252.10, ideally with rates stable. Invalidation/downside: below $238.30, then $226.94. Risks: project delays, working capital, customer concentration, competition, rates and valuation. Vertiv IR
LLY — Eli Lilly
NYSE · mega-cap pharma · high event risk. Classification/horizon: watch stabilization; 1–4 weeks and 3–12+ months. Thesis/catalyst: Phase 3 retatrutide efficacy supports a broad metabolic franchise. Evidence/counter: sponsor-reported TRIUMPH-2 randomized placebo-controlled n=1,152 showed 20.8% mean loss at 80 weeks on 12 mg versus 4.0% placebo; GI adverse events, 7.3% dysesthesia and 7.7% discontinuation at 12 mg matter. LLY closed $1,149.85 below its $1,152.05 20-day average. Entry: reclaim $1,158.72; stronger above $1,215. Invalidation/downside: below $1,139.85 then $1,113.29; long-term regulatory/safety/CMC setback. Risks: approval, manufacturing, payer access, competition and valuation. Lilly data
NVO — Novo Nordisk ADR
NYSE ADR / Copenhagen · mega-cap pharma · medium/high risk. Classification/horizon: no bottom-fishing; 1–4 weeks and 3–12+ months. Thesis/catalyst: Wegovy/CagriSema/oral pipeline preserves optionality, and EASD generated multiple positive sponsor releases. Evidence/counter: $37.40 close, −1.35%, at a new 20-day low and 20% below one month ago despite positive headlines—price rejects the news. Entry: higher low plus reclaim $37.97; stronger above $41.61 20-day average. Invalidation/downside: sustained close below $37.37 or adverse regulatory action. Risks: differentiation versus Lilly, pricing, CMC, market share, ADR/FX and sponsor-release bias. Novo archive
Changes versus the 2026-10-01 report
- Regime: neutral/bifurcated becomes neutral/cautious: futures are positive, but oil above $92, Friday's Asian selloff and payroll/event risk reduce conviction.
- MU: remains #1 and gains tape confirmation after +3.03%; trigger moves to $1,108.72. It is still conditional because the move is extended and macro-sensitive.
- NVDA: remains #2; fresh GPT-6/Blackwell platform evidence helps, but below-average volume and payrolls keep confirmation mandatory.
- Quantum: avoid-chase retained. D-Wave's simulator beta is acknowledged but did not create a volume-backed basket breakout or prove material economics.
- VRT: remains watch; Thursday's rebound did not reclaim its 20-day average.
- LLY/NVO: remain watch-only. NVO's fresh positive EASD release failed to stop a new 20-day low; this divergence is a warning, not a bargain signal.
- COHR/CRDO: added to watch after outsized connectivity moves; both require non-chasing entries, and COHR's move lacked a same-day primary release in the accessible company feed.
- VKTX: removed from the top-five watchlist after −6.41%; binary clinical and financing risks remain, but there is no confirmed entry.
Important 7–30 day catalysts
Oct. 2 · 14:30 CEST — U.S. September employment. Payrolls, unemployment, wages, participation and revisions. BLS
Oct. 6 · 14:30 CEST — U.S. August trade balance. GDP tracking, dollar and tariff transmission. BEA
Oct. 7 · 20:00 CEST — FOMC minutes. September 15–16 meeting. Fed
Oct. 14–16 — CPI, PPI and import/export prices. Key test after the oil shock. BLS
October · exact date unverified — CagriSema FDA review window. Novo has said review is expected in 2026; no exact action date is asserted. Novo
Oct. 27–28 — FOMC meeting. Jobs, CPI and oil can materially change pricing. Fed
Oct. 29 — Q3 GDP advance and September PCE. Releases occur after Europe's seasonal clock change. BEA
Bottom line by horizon
Trade after the data, not before it
MU/NVDA only if stated breakouts hold after 14:30 CEST and the 10-year/oil do not accelerate. Do not chase COHR/CRDO or quantum.
Biggest risk: payroll-driven reversal. Invalidation: MU below $1,022.90 or NVDA below $228.16.
Prefer verified earnings momentum
MU has the strongest catalyst; NVDA has the cleaner platform quality. Keep optical names watch-only until they digest gains.
Biggest risk: oil plus firm labor data reprice the long end. Invalidation: closes below stated 20-day averages or estimate cuts.
Cash flow over narrative
Stage AI entries; require operating cash flow and durable demand. Treat quantum and clinical-stage biotech as venture/binary exposure. For peptides, separate efficacy from safety, CMC, access and price response.
Biggest risk: normalized earnings cannot support valuation. Invalidation: guide cuts, contract slippage, regulatory setbacks or financing stress.
Data quality & source controls
What was verified
- Live retrievals covered CNBC, Yahoo chart endpoints, official Treasury/BLS/Fed/SEC/EMA, NVIDIA, Coherent, Novo, IonQ and D-Wave.
- Market closes and technical levels are calculated from Yahoo daily OHLCV through Oct. 1; CNBC independently cross-checked major indices, futures, Asia, oil and the jobs consensus.
- Treasury 2Y/10Y are official Oct. 1 closes. Intraday 10Y high comes from CNBC and is labeled separately.
- Company/product/clinical statements use primary releases where available. Sponsor biotech releases are not peer review or regulatory approval.
Limitations and exact handling
- Europe was not open at cutoff; Thursday closes are shown, not Friday performance. Mainland China remained on holiday, so Shanghai is a Sept. 30 reference.
- CNBC/Yahoo futures differ slightly by timestamp. They are indications, not executable broker quotes.
- Coherent's accessible release page showed no Oct. 1 company catalyst; therefore the +10.90% move is not assigned an invented cause. Credo's guessed deep-link returned 404, so no unverified same-day catalyst is claimed.
- IonQ's dynamic IR page did not render its news list through direct curl, so indexed primary IR results were used; no post-Sept. 24 IonQ release was asserted.
- FDA's attempted press-announcement URL returned 404; EMA and company sources were checked instead. No new obesity approval is claimed.
- No borrow availability, fee, real-time spread or guaranteed stop execution is claimed.
Clickable source ledger
- CNBC U.S./global live update, Oct. 2 — futures, cash session, Asia, yields, oil, jobs consensus and Fed pricing.
- U.S. Treasury daily curve — Oct. 1 official yields.
- BLS October calendar; Fed calendar; BEA schedule.
- SEC releases — current regulatory actions.
- Micron FY26 results.
- NVIDIA newsroom — Oct. 1 GPT-6 Astra/Blackwell item.
- Coherent releases — PhotonLink and absence of a listed Oct. 1 release at cutoff.
- IonQ news; D-Wave releases.
- Novo archive; Lilly TRIUMPH data; EMA updates.